Kevin P. Kerns

Array ( [id] => 12178681 [patent_doc_number] => 20180037617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/505600 [patent_app_country] => US [patent_app_date] => 2015-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 38688 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15505600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866210 [patent_doc_number] => 20170233495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'ANTIBODIES SPECIFIC FOR MMP9' [patent_app_type] => utility [patent_app_number] => 15/503447 [patent_app_country] => US [patent_app_date] => 2015-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 37311 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026441 [patent_doc_number] => 10035836 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-07-31 [patent_title] => Modified IL-2 variants that selectively activate regulatory T cells [patent_app_type] => utility [patent_app_number] => 15/327813 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 9710 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15327813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700561 [patent_doc_number] => 20160046707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'NEUTRALIZING ANTI-CCL20 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/816989 [patent_app_country] => US [patent_app_date] => 2015-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 38629 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14816989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11297841 [patent_doc_number] => 09505837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-29 [patent_title] => 'Anti-IL-23 antibodies' [patent_app_type] => utility [patent_app_number] => 14/812375 [patent_app_country] => US [patent_app_date] => 2015-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 33817 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14812375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430227 [patent_doc_number] => 20150315239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/805424 [patent_app_country] => US [patent_app_date] => 2015-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18482 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14805424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757289 [patent_doc_number] => 20170204156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN' [patent_app_type] => utility [patent_app_number] => 15/326936 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 13079 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678021 [patent_doc_number] => 20160024167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'METHODS AND COMPOSITIONS BASED ON DIPHTHERIA TOXIN-INTERLEUKIN-3 CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/802398 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 50574 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14802398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10679560 [patent_doc_number] => 20160025705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'PROCESS FOR ASSESSING RISK OF SUBSTANCE ADMINISTRATION' [patent_app_type] => utility [patent_app_number] => 14/796091 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5813 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663640 [patent_doc_number] => 20160009783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'OLIGOMERS FOR TNF SUPERFAMILY INHIBITION, METHODS OF MAKING AND USING' [patent_app_type] => utility [patent_app_number] => 14/796827 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 24052 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729329 [patent_doc_number] => 20170190772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'TREATMENT OF LYSOSOMAL DISORDERS (IL-1 ANTAGONISTS)' [patent_app_type] => utility [patent_app_number] => 15/325368 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14767 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627322 [patent_doc_number] => 20170137511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'ANTIBODIES TO IL-15' [patent_app_type] => utility [patent_app_number] => 15/320763 [patent_app_country] => US [patent_app_date] => 2015-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22493 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15320763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851736 [patent_doc_number] => 20170226228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Compositions and Methods to Regulate Renalase in the Treatment of Diseases and Disorders' [patent_app_type] => utility [patent_app_number] => 15/321015 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 42492 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15321015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12043371 [patent_doc_number] => 09820955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes' [patent_app_type] => utility [patent_app_number] => 14/752487 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 19868 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14752487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649189 [patent_doc_number] => 20170145089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'ANTI-IL4-IL 13 BISPECIFIC ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/320106 [patent_app_country] => US [patent_app_date] => 2015-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 18520 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15320106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10988902 [patent_doc_number] => 20160185846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/746555 [patent_app_country] => US [patent_app_date] => 2015-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26650 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14746555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11547281 [patent_doc_number] => 09616104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-11 [patent_title] => 'Method for treating osteoarthritis using dominant negative tissue necrosis factor' [patent_app_type] => utility [patent_app_number] => 14/744941 [patent_app_country] => US [patent_app_date] => 2015-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 17226 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14744941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757493 [patent_doc_number] => 20170204362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'CELL CULTURE METHODS AND MEDIA COMPRISING N-ACETYLCYSTEINE' [patent_app_type] => utility [patent_app_number] => 15/318798 [patent_app_country] => US [patent_app_date] => 2015-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15445 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15318798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15816515 [patent_doc_number] => 10633423 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => IL-6-binding polypeptide complex [patent_app_type] => utility [patent_app_number] => 15/317633 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 62 [patent_no_of_words] => 32603 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15317633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14913691 [patent_doc_number] => 10428152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-01 [patent_title] => Antibodies directed against CD127 [patent_app_type] => utility [patent_app_number] => 15/317355 [patent_app_country] => US [patent_app_date] => 2015-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35328 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15317355 [rel_patent_id] =>[rel_patent_doc_number] =>)